LFVN Lifevantage Corp
Data as of close
Healthcare · Pharmaceutical Preparations
Lifevantage Corp (LFVN) is a healthcare company in the Pharmaceutical Preparations industry, with a market capitalization of $74 million. Shares last traded at $5.93, 50.1% below their 52-week high. Over the past year the stock is down 27.2%. LFVN trades at a price-to-earnings ratio of 14.65, below the Pharmaceutical Preparations median of 17.04. Net profit margin is 2.8%, above the peer median of -7.6%. Revenue declined 20.1% year over year. The shares yield 3.1% in dividends.
* P/E (TTM) = market cap ÷ net income over the trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year — the same basis as the peer table and the screener, so it can differ from price ÷ EPS.
Performance
Chart
Full chart →Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.
Technicals
Financials
Trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year; revenue is the fiscal-year figure where quarterly revenue covers under half of it (typical for banks, insurers and REITs), and margins are taken on it; latest reported period ends 2026-06-30. Source: SEC EDGAR/XBRL.
LFVN Dividend History
| Fiscal year end | Total dividends paid | Per share* | Payout ratio |
|---|---|---|---|
| 2026-06-30 | $2M | $0.18 | 46% |
| 2025-06-30 | $2M | $0.16 | 21% |
| 2024-06-30 | $7M | $0.53 | 236% |
| 2023-06-30 | $2M | $0.13 | 62% |
| 2022-06-30 | $0M | $0.03 | 12% |
*Per share derived as total dividends paid ÷ weighted diluted shares (SEC EDGAR/XBRL annual cash-flow facts). Reported history — not a forecast of future dividends.
Compare payers on the highest-dividend-yield screener.
Recent earnings
| Period | EPS (diluted) | Reported |
|---|---|---|
| Q4 2026 (derived) | $0.10 | 2026-08-27 |
| FY 2026 | $0.40 | 2026-08-27 |
| Q3 2026 | $0.11 | 2026-05-06 |
| Q2 2026 | $0.02 | 2026-02-04 |
| Q1 2026 | $0.17 | 2025-11-04 |
| Q4 2025 (derived) | $0.16 | 2025-09-04 |
Q4 marked "derived" = fiscal-year EPS minus Q1–Q3 (10-Ks report only the annual figure); EPS is not strictly additive, so it can differ by a cent or two from the issuer's own Q4.
Pharmaceutical Preparations peers
LFVN vs 14 industry peers (Pharmaceutical Preparations), by market cap. Data as of close
| LLY | Lilly (Eli) | $1.33T | 48.13 | 15.35 | 31.9% | -0.28% |
| JNJ | Johnson & Johnson | $652.2B | 40.52 | 6.57 | 16.2% | -0.82% |
| ONC | Beone Medicines Ltd. | $533.8B | 814.05 | 87.09 | 10.7% | -2.48% |
| ABBV | AbbVie | $510.3B | 80.87 | 7.93 | 9.8% | -2.05% |
| MRK | Merck | $366.4B | 115.46 | 5.50 | 4.8% | -0.22% |
| ABT | Abbott Laboratories | $192.1B | 30.61 | 4.26 | 13.9% | +3.81% |
| PFE | Pfizer | $175.0B | 40.41 | 2.75 | 6.8% | +0.69% |
| VRTX | Vertex Pharmaceuticals | $144.5B | 32.80 | 11.48 | 35.0% | +1.96% |
| BMY | Bristol Myers Squibb | $128.8B | 13.94 | 2.58 | 18.5% | +0.90% |
| REGN | Regeneron Pharmaceuticals | $99.4B | 20.64 | 5.89 | 28.5% | +3.63% |
| TEVA | Teva Pharmaceutical Industries Ltd | $47.4B | 67.14 | 2.74 | 4.1% | -3.35% |
| ZTS | Zoetis | $34.4B | 13.14 | 3.61 | 27.5% | +4.35% |
| RPRX | Royalty Pharma Plc | $29.6B | 36.35 | 11.68 | 32.1% | -0.98% |
| ROIV | Roivant Sciences Ltd. | $25.9B | — | 3441.87 | — | -2.76% |
Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.